PRVB - Provention Bio -5.9% AH as company announces public offering

Provention Bio (PRVB) commences an underwritten public offering of 6M shares of its common stock.Underwriters' option to purchase up to an additional 900,000 shares.Company intends to use its net proceeds for (i) pre-commercial activities, potential commercial activities, potential milestone or royalty payments, clinical development, and regulatory and manufacturing activities for PRV-031; (ii) development activities for PRV-015, PRV-101, and PRV-3279; (iii) the potential acquisition or in-licensing of other product candidates; and (iv) for other general corporate purposes.Shares -5.9% after hoursPress Release

For further details see:

Provention Bio -5.9% AH as company announces public offering